InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: None

Wednesday, 07/24/2019 1:23:43 PM

Wednesday, July 24, 2019 1:23:43 PM

Post# of 892
Multiple catalysts are expected here in the 2nd half of 2019, what's not to like about TYME. I can't believe this biotech is only trading at $1.17 per share.

1.) Preclincial data of SM-88 in multiple types of cancer
2.) Initiation of PanCan Precision pivotal study for 2nd line pancreatic cancer
3,) Initiation for 3rd line pivotal pancreatic cancer trial
4,) full results from phase 2 prostate cancer study